Scancell Holdings plc (LON:SCLP - Get Free Report) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 11.90 ($0.15) and traded as low as GBX 8.25 ($0.11). Scancell shares last traded at GBX 8.25 ($0.11), with a volume of 440,305 shares changing hands.
Scancell Trading Down 9.4 %
The business's fifty day moving average is GBX 8.94 and its two-hundred day moving average is GBX 11.77. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The firm has a market cap of £79.49 million, a price-to-earnings ratio of -11.77 and a beta of 0.35.
Scancell (LON:SCLP - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. Equities analysts anticipate that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.
Scancell Company Profile
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
See Also
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
